Document is current

Article History

Received: 16 May 2024

Accepted: 8 October 2024

First Online: 25 October 2024

Competing interests

: JS has received honoraria as a consultant and/or advisory board member for Abbvie, Aldena, Amgen, AObiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, BioMX, Biosion, Bodewell, Boehringer-Ingelheim, Bristol Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, Corevitas, Dermavant, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Invea, Kiniksa, Leo Pharma, My-Or Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate; speaker for Abbvie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme; stock/stock options for Connect, Verdant; institution received grants from Galderma, Incyte, Pfizer DR has consulted, spoken for, or conducted trials for the following companies: AbbVie, Abcuro, AltruBio, Amgen, Arena, Boehringer-Ingelheim, Bristol Meyers Squibb, Celgene, Concert, CSL Behring, Dermavant, Dermira, Galderma, Incyte, Janssen, Kyowa Kirin, Lilly, Merck, Nektar, Novartis, Pfizer, RAPT, Regeneron, Recludix, Revolo Biotherapeutics, Sanofi, Sun Pharmaceuticals, UCB, VielaBio, Zura Bio. RC has served as an advisor, consultant, speaker, and/or investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRexBio, and UCB. TB has been a speaker and/or consultant and/or Investigator for AbbVie, Affibody, Almirall, Amagma, AnaptysBio, AOBiom, Apogee, Arena, Aristea, Artax, Asana Biosciences, ASLAN pharma, Astria, Attovia, Bayer Health, Biofilm control, BioVerSys, Böhringer-Ingelheim, Bristol-Myers Squibb, Connect Pharma, Daichi-Sanyko, Dermavant, DICE Therapeutics, Domain Therapeutics, DS Pharma, EQRx, Galderma, Galapagos, Glenmark, GSK, Incyte, Innovaderm, IQVIA, Janssen, Kirin, Kymab, LEO, LG Chem, Lilly, L´Oréal, MSD, Medac, Micreos, Nektar, Novartis, Numab, OM-Pharma, Overtone, Pfizer, Pierre Fabre, Q32bio, RAPT, Samsung Bioepis, Sanofi/Regeneron, TIRmed, UCB, Union Therapeutics, UPStream Bio, YUHAN. He is founder and chairman of the board of the non-profit biotech Davos Biosciences within the international Kühne-Foundation. SS has received research funding from Eli Lilly and Company, Amgen, Galderma, HighLight Therapeutics, Encube, Cara Therapeutics, Vyne, Novan, AstraZeneca. Honoria for Nektar. Consulting/Advisory Role for Nektar. LB has been a consultant and/or investigator for Abbvie, Allakos, Amgen, Arcutis, Arena Pharmaceuticals, AstraZeneca, Astria Therapeutics, Evelo Biosciences, Escient Pharma, Galderma, Incyte, Invea Therapeutics, Janssen, LEO Pharma, Merck, Nektar Therapeutics, Novartis, Numab Therapeutics, Pfizer, Rapt Therapeutics, Regeneron Pharmaceuticals Inc., Ribon Therapeutics, Sanofi-Aventis/Genzyme, Sitryx Therapeutics, Stealth BioTherapeutics, Trevi Therapeutics, UCB Pharma, Union therapeutics, and Xencor. MG has been an investigator, speaker and/or advisor for: AbbVie, Acelyrin, Amgen, Akros, Arcutis, Aristea, AnaptysBio, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara, Dermira, Dermavant, Eli Lilly, Galderma, GSK, Incyte, InMagene, JAMP Pharma, Janssen, Kyowa Kirin, LEO Pharma, L’Oreal, MedImmune, Meiji, Moonlake, Nektar, Nimbus, Novartis, Pfizer, Regeneron, Roche, Sanofi Genzyme, Sun Pharma, Tarsus, Takeda, UCB, Union, Ventyx and Vyne. SC, CF, DY, YL, BK, TM, MT, and JZ are employees and stockholders at Nektar Therapeutics. MT also has a leadership role and is a shareholder in Enzo Biochem and RayzeBio. CS and AN are shareholders at Eli Lilly and Company. AN is a shareholder at Recludix Pharma. JL is a stockholder in Eli Lilly and Company.